The World Anti-Doping Agency (WADA) has provisionally suspended the WADA accreditation of the Laboratory of the Agence Française de lutte contre le Dopage (the National Anti-Doping Organization of France) in Châtenay-Malabry, France (Paris Laboratory). This provisional suspension was imposed due to analytical issues self-reported to WADA by the Laboratory.
The provisional suspension, which took effect on 24 September 2017, prohibits the Paris Laboratory from carrying out any anti-doping activities, including all analyses of urine and blood samples. The provisional suspension will remain in place pending disciplinary proceedings being carried out by an independent Disciplinary Committee, which will be mandated to make a recommendation to the Chair of the WADA Executive Committee regarding the status of the Laboratory’s WADA accreditation.
During the period of the provisional suspension, samples that have not yet been analyzed by the Paris Laboratory; samples currently undergoing a confirmation procedure; and, any samples for which an Adverse Analytical Finding has been reported; must be securely transported to another WADA-accredited laboratory. This is in order to ensure continued high quality sample analysis, which also helps preserve athletes’ confidence in this process and of the wider anti-doping system.
According to the International Standard for Laboratories (ISL), WADA is responsible for accrediting and re-accrediting anti-doping laboratories, thereby ensuring that they maintain the highest quality standards. This monitoring process is conducted in conjunction with International Organization for Standardization (ISO) assessment by independent national accreditation bodies that are full members of the International Laboratory Accreditation Cooperation (ILAC).